Virginia's Veto Shock, TSA Clears Medical Cannabis, & Tariff Trouble

Editor's Brief

Friday, May 22, 2026 — Virginia's Democratic governor just handed the cannabis industry one of its most stunning betrayals of the year, vetoing an adult-use sales bill she campaigned on signing. Meanwhile, the TSA quietly updated its policy to allow medical cannabis on flights, a tangible win for patients that flew under the radar. Add in a fresh analysis showing tariffs could gut the financial benefits of 280E relief, and you've got a news cycle that perfectly captures this industry's two-steps-forward, one-step-back reality.

Top Story

Virginia Governor Spanberger Vetoes Adult-Use Sales Bill — Breaking Her Own Campaign Promise

Virginia Gov. Abigail Spanberger (D) vetoed legislation this week that would have launched the state's long-awaited adult-use cannabis retail market, stunning her own party's lawmakers and cannabis advocates across the country. Spanberger, who explicitly promised voters she would sign a cannabis sales bill, cited the legislation as "rushed" — a justification her Democratic colleagues in the legislature are openly calling a betrayal.

The backstory matters here. Virginia has had legal adult-use possession since 2021, but retail sales have been stuck in legislative limbo for years. This bill was supposed to finally close that gap. Instead, the veto pushes legal sales to 2028 at the earliest — meaning Virginians will continue buying weed through unregulated channels despite it being perfectly legal to possess.

The political fingerprints on this veto are worth examining. Reports indicate the hemp lobby and Total Wine — two industries with financial stakes in keeping the retail cannabis market closed or shaped to their advantage — actively pushed for the veto. That context reframes Spanberger's "rushed" framing as something more transactional than principled.

For consumers and home growers in Virginia, the practical reality is stark: possession remains legal, but a regulated retail supply chain is off the table for at least two more years. Watch for a significant legislative backlash when the General Assembly reconvenes, and expect this veto to become a defining issue in Virginia's 2027 state elections.

Policy & Legalization

Tariffs Could Erase 280E Rescheduling Benefits for Many Cannabis Businesses

A sharp new op-ed from the Cannabis Research Institute argues that federal tariffs will redistribute — not eliminate — the financial gains from 280E tax relief following cannabis rescheduling. The analysis suggests dispensary-heavy companies stand to benefit most, while multistate operators (MSOs) reliant on imported equipment, packaging, or supplies could see tariff costs offset their tax savings entirely. This is a must-read for anyone tracking cannabis investment or business strategy in 2026.

Efforts to Repeal Cannabis Legalization Losing Momentum Nationally

A new report from GreenState confirms what advocates have long argued: cannabis legalization, once passed, is politically almost impossible to roll back. Repeal efforts in multiple states have stalled or collapsed entirely, suggesting that legal markets — even imperfect ones — become entrenched quickly. For the industry, this is quiet but significant long-term good news.

Psilocybin Rescheduling Pressure Mounts on DEA

An attorney representing the doctor behind the original DEA psilocybin rescheduling petition is pushing hard for the agency to "promptly move forward" in light of President Trump's recent executive order signaling support for psychedelic medicine. The DEA's prolonged delays on the petition are increasingly difficult to defend politically, and movement here could signal broader momentum for alternative plant medicines beyond cannabis.

Business & Markets

TSA Now Allows Medical Cannabis on Flights

The Transportation Security Administration updated its official guidance on April 27 to permit travelers to fly with medical cannabis, a direct consequence of the federal reclassification of cannabis to Schedule III. This is a meaningful quality-of-life change for medical patients who travel. However, a critical caveat remains: USDOT confirmed this week that safety-sensitive transportation workers — truckers, pilots, bus drivers — still face zero-tolerance drug testing regardless of medical card status.

'Reckless' 280E Gamble Backfires on Cannabis MSO

MJBizDaily reports that a cannabis multistate operator is facing federal demands for millions of dollars after an aggressive and apparently poorly-advised 280E tax strategy collapsed. The case is a stark warning: rescheduling doesn't retroactively forgive creative accounting. Cannabis businesses that gambled on 280E workarounds before rescheduling was finalized are now paying the price.

NLRB Rules Cannabis Cultivation Workers Can Unionize

The National Labor Relations Board rejected a Missouri cannabis company's argument that cultivation and manufacturing workers qualify as agricultural workers — a classification that would have stripped them of unionization rights. Workers at BeLeaf Medical's Sinse facility now have a clear legal path to organize. This ruling sets a significant precedent for labor rights across the cannabis cultivation sector nationally.

Science & Cultivation

Psychosis and Cannabis Legalization: Where's the Evidence?

MedPage Today published a critical look at the long-standing claim that cannabis legalization increases psychosis rates — and found the evidence remains weak and inconsistent. For growers and consumers, this matters: it undercuts a primary argument used by prohibition advocates and suggests that legalization opponents are working harder than the science supports. Expect this research to be cited heavily in upcoming legalization debates.

Global Cannabis Prices Continue Structural Decline

A new Forbes-covered global report confirms what anyone watching legal markets already suspects: cannabis prices were always going to fall as legalization expanded, and that trajectory isn't reversing. For home growers, this is actually vindicating — the economic case for cultivating your own has never been stronger as retail prices compress margins but dispensary convenience premiums remain. Quality craft genetics continue to hold value where commodity flower does not.

Culture & Community

Scary Movie Goes Full Stoner — A PAX Vape Collab and a Bong Popcorn Bucket

The Wayans brothers' new Scary Movie reboot is leaning hard into cannabis culture with an official PAX vaporizer collaboration, a stoner parody series, and a bong-shaped popcorn bucket that broke the internet (though nobody can confirm it's actually for sale). It's a cultural milestone worth noting: a major Hollywood studio explicitly marketing to cannabis consumers is mainstream now. The stigma isn't just fading — Hollywood is actively monetizing its absence.

Ilhan Omar: "A Lot of People" in Congress Smoke Weed

Rep. Ilhan Omar, co-chair of the Congressional Cannabis Caucus, told TMZ that "a lot of people" in Congress use cannabis, flashed a peace sign, and walked off. Underneath the viral moment is a genuine point about the disconnect between congressional behavior and federal cannabis policy. She also gave surprising credit to Trump for movement on rescheduling — a bipartisan moment worth watching.

What This Means for Growers

• Virginia home growers are on their own for at least two more years. With retail sales vetoed until 2028 at earliest, cultivating your own remains the most reliable path to quality, legal cannabis in the state.
• Cannabis prices will keep falling at retail. The Forbes global report confirms long-term price compression in legal markets — home cultivation increasingly offers better quality-per-dollar than dispensary flower, especially for craft genetics.
• TSA's new medical cannabis policy is real but limited. You can fly with your medicine now, but if your job involves operating vehicles or heavy machinery under federal safety rules, nothing has changed — zero tolerance remains.
• Rescheduling's business benefits are messier than advertised. The tariff/280E analysis and the MSO tax blowup are reminders that federal policy changes create winners and losers — the regulatory environment for commercial grows is still volatile.
• Labor rights in cultivation facilities are expanding. The NLRB ruling on unionization matters for anyone working in or thinking about commercial cultivation — workers now have clearer legal standing to organize across the sector.

Quick Links

Full source links are listed below this article.